2021 Archives - Ryvu Therapeutics

March 15, 2022

Ryvu Therapeutics S.A. Annual Report 2021

Read More

December 30, 2021

Ryvu Therapeutics to receive from Menarini Group a development milestone based on an amended global License Agreement

Read More

December 20, 2021

Ryvu Therapeutics receives approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Spain

Read More

December 17, 2021

Change order to the statement of work

Read More

December 14, 2021

Galapagos NV exercises its exclusive option to license program with therapeutic potential in inflammatory diseases

Read More

December 13, 2021

Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology (ASH) Annual Meeting and the 44th San Antonio Breast Cancer Symposium

Read More

November 19, 2021

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

Read More

November 10, 2021

Ryvu Therapeutics S.A. Q3 2021 Financial Report

Read More

November 9, 2021

Ryvu Therapeutics to highlight HPK1 and STING Programs at the upcoming SITC Conference

Read More

November 4, 2021

Ryvu’s partner Menarini Group receives FDA Orphan Drug Designation for SEL24 (MEN1703) for the Treatment of Acute Myeloid Leukemia

Read More